FMP

FMP

Enter

BMY - Bristol-Myers Squibb...

photo-url-https://images.financialmodelingprep.com/symbol/BMY.png

Bristol-Myers Squibb Company

BMY

NYSE

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

46.45 USD

-0.43 (-0.926%)

Operating Data

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

42.52B

46.38B

46.16B

45.01B

48.3B

52.41B

56.86B

61.69B

66.93B

72.62B

Revenue %

-

9.09

-0.49

-2.5

7.32

8.5

8.5

8.5

8.5

Ebitda

5.04B

20.19B

19.23B

19.42B

3.22B

15.39B

16.7B

18.12B

19.66B

21.33B

Ebitda %

11.84

43.53

41.66

43.14

6.66

29.37

29.37

29.37

29.37

Ebit

-5.45B

9.43B

8.95B

9.61B

-6.38B

3.67B

3.98B

4.32B

4.69B

5.09B

Ebit %

-12.82

20.33

19.38

21.34

-13.21

7.01

7.01

7.01

7.01

Depreciation

10.49B

10.76B

10.29B

9.81B

9.6B

11.72B

12.72B

13.8B

14.97B

16.24B

Depreciation %

24.66

23.19

22.29

21.8

19.88

22.36

22.36

22.36

22.36

Balance Sheet

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Total Cash

14.55B

13.98B

9.12B

12.28B

10.86B

14.03B

15.22B

16.52B

17.92B

19.45B

Total Cash %

34.21

30.14

19.76

27.29

22.48

26.78

26.78

26.78

26.78

Receivables

8.5B

12.52B

13.94B

15.26B

11.13B

14.06B

15.25B

16.55B

17.96B

19.48B

Receivables %

19.99

26.98

30.19

33.92

23.05

26.83

26.83

26.83

26.83

Inventories

2.07B

2.1B

2.34B

2.66B

2.56B

2.69B

2.92B

3.17B

3.44B

3.73B

Inventories %

4.88

4.52

5.07

5.91

5.29

5.13

5.13

5.13

5.13

Payable

2.71B

2.95B

3.04B

3.26B

3.6B

3.57B

3.87B

4.2B

4.55B

4.94B

Payable %

6.38

6.36

6.59

7.24

7.46

6.8

6.8

6.8

6.8

Cap Ex

-753M

-973M

-1.12B

-1.21B

-1.25B

-1.21B

-1.31B

-1.43B

-1.55B

-1.68B

Cap Ex %

-1.77

-2.1

-2.42

-2.69

-2.58

-2.31

-2.31

-2.31

-2.31

Weighted Average Cost Of Capital

Price

46.45

Beta

Diluted Shares Outstanding

2.03B

Costof Debt

4

Tax Rate

After Tax Cost Of Debt

4

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

51.2B

Total Equity

94.15B

Total Capital

145.35B

Debt Weighting

35.22

Equity Weighting

64.78

Wacc

5.12

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

42.52B

46.38B

46.16B

45.01B

48.3B

52.41B

56.86B

61.69B

66.93B

72.62B

Ebitda

5.04B

20.19B

19.23B

19.42B

3.22B

15.39B

16.7B

18.12B

19.66B

21.33B

Ebit

-5.45B

9.43B

8.95B

9.61B

-6.38B

3.67B

3.98B

4.32B

4.69B

5.09B

Tax Rate

-6.79

-6.79

-6.79

-6.79

-6.79

-6.79

-6.79

-6.79

-6.79

-6.79

Ebiat

-7.14B

8.15B

7.34B

9.13B

-6.81B

3.4B

3.69B

4.01B

4.35B

4.72B

Depreciation

10.49B

10.76B

10.29B

9.81B

9.6B

11.72B

12.72B

13.8B

14.97B

16.24B

Receivables

8.5B

12.52B

13.94B

15.26B

11.13B

14.06B

15.25B

16.55B

17.96B

19.48B

Inventories

2.07B

2.1B

2.34B

2.66B

2.56B

2.69B

2.92B

3.17B

3.44B

3.73B

Payable

2.71B

2.95B

3.04B

3.26B

3.6B

3.57B

3.87B

4.2B

4.55B

4.94B

Cap Ex

-753M

-973M

-1.12B

-1.21B

-1.25B

-1.21B

-1.31B

-1.43B

-1.55B

-1.68B

Ufcf

-5.27B

14.13B

14.93B

16.3B

6.12B

10.81B

13.97B

15.16B

16.45B

17.85B

Wacc

5.12

5.12

5.12

5.12

5.12

Pv Ufcf

10.29B

12.64B

13.05B

13.47B

13.9B

Sum Pv Ufcf

63.36B

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

5.12

Free Cash Flow T1

18.2B

Terminal Value

583.44B

Present Terminal Value

454.54B

Intrinsic Value

Enterprise Value

517.9B

Net Debt

40.85B

Equity Value

477.04B

Diluted Shares Outstanding

2.03B

Equity Value Per Share

235.34

Projected DCF

235.34 0.803%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep